Cartesian Therapeutics, Inc. Cash Flow Statement
RNAC|8 years of annual SEC 10-K data (FY2016-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 8 fiscal years. All figures from audited SEC 10-K filings.
Cartesian Therapeutics, Inc. used $24M in operating cash flow and negative free cash flow of $33M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -0.06 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2016 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$77.4M | -$219.7M | -$25.7M | -$68.9M | -$55.4M | -$65.3M | -$65.3M | -$12.9M |
| Depreciation & Amortization | $1.2M | $700.0K | $600.0K | $600.0K | $700.0K | $1.0M | $750.0K | $864.0K |
| Operating Cash Flow | -$23.7M | -$51.2M | -$60.4M | $34.9M | -$51.4M | -$59.2M | -$52.0M | -$12.7M |
| Capital Expenditures | $9.1M | $206.0K | $1.1M | $815.0K | $47.0K | $884.0K | $733.0K | $227.0K |
| Free Cash Flow | -$32.8M | -$51.4M | -$61.5M | $34.1M | -$51.5M | -$60.0M | -$52.8M | -$12.9M |
| FCF Margin | -84.2% | -197.5% | -72.3% | 205.3% | -771.0% | -6649.5% | -25487.4% | -424.8% |